References	Drug Study	Design	Evidence level	Dose	Age(years)	Number of patients	Responders (%) Active drug	Responders (%) Placebo	p value
Hamalainen et al 1997	Ibuprofen	RCT	A	10 mg/kg	4–16	88	68	37	<0.05< /td>
Lewis et al 2002	Ibuprofen	RCT		7.5 mg/kg	6–12	84	76	53	0.006
Evers et al 2006	Ibuprofen	RCT		200–400 mg	6–18	32	69	28	<0.05< /td>
Hamalainen 1997	Acetaminophen	RCT	B	15 mg/kg	4–16	88	54	37	<0.05< /td>
Hamalainen et al 1997	Dihydroergotamine	RCT	C	20,40 microg/kg	5–15	12	58	16	NS
Ueberall 1999	Sumatriptan nasal	RCT	A	20 mg	6–10	14	86	43	0.03
Winner et al. 2001	Sumatriptan nasal	RCT		5–10–20 mg	12–17	510	66*	53	<0.05< /td>
Ahonen et al. 2004	Sumatriptan nasal	RCT		10–20 mg	8–17	83	64	39	0.003
Winner et al. 2006	Sumatriptan nasal	RCT		20 mg	12–17	738	61	52	NS
Hamalainen et al. 1997	Sumatriptan oral	RCT	C	50–100 mg	8–16	23	30	22	NS
Mac Donald 1994	Sumatriptan sc.	OT	C	3–6 mg	6–16	17	64	–	–
Linder 1996	Sumatriptan sc.	OT		0.06 mg/kg	6–18	50	78	–	-
Winner et al. 2002	Rizatriptan	RCT	C	5 mg	12–17	196	66	56	NS
Visser et al. 2004	Rizatriptan	RCT		5 mg	12–17	234	68	69	NS
Visser et al. 2004	Rizatriptan	OT		5 mg	12–17	686	77	–	–
Linder and Dowson 2000	Zolmitriptan oral	OT	C	2.5–5 mg	12–17	38	88–70	–	–
Evers et al. 2006	Zolmitriptan oral	RCT		2.5 mg	6–18	32	62	28	<0.05< /td>
Charles 2006	Almotriptan oral	OT	B	6.25–12.5 mg	11–17	15	86	–	–
Linder et al. 2008	Almotriptan oral	RCT		6.25–12.5–25 mg	12–17	866	67–73	55	<0.001< /td>

Evidence level

• Level A: two or more clinically controlled, randomized studies carried out according to good clinical practice (GCP), versus placebo or versus active treatment of proven efficacy.
• Level B: one clinically controlled, randomized study carried out according to GCP or more than one well-designed clinical case–control study or cohort study
• Level C: favourable judgment of two-third of the Ad Hoc Committee members, historical controls, non-randomized studies, case reports
• NS no statistically significant difference between active drug and placebo, RCT randomized controlled trial, OT open trial

^*5 mg

Migraine prophylaxis

---

Cite this: ICNApedia contributors.Symptomatic drugs for migraine management evaluated in placebo-controlled and open clinical trials. ICNApedia, The Child Neurology Knowledge Environment. 24 June 2024. Available at: https://icnapedia.org/knowledgebase/articles/symptomatic-drugs-for-migraine-management-evaluated-in-placebo-controlled-and-open-clinical-trials Accessed  24 June 2024.